US-based cancer-focused biopharmaceutical company Constellation Pharmaceuticals raised $100m today in a funding round backed by SR One, the corporate venturing arm of healthcare group GlaxoSmithKline.
The round also featured financial services conglomerate Fidelity Management and Research, University of California Investment Office, Cormorant Asset Management, Deerfield Management, Hillhouse Capital, NS Investment, OrbiMed and Sirona Capital.
Venrock Healthcare Partners, Column Group, Third Rock Ventures, Topspin Partners and Casdin Capital filled out the investors.
Founded in 2008, Constellation is working on immuno-oncology therapies…